These include: Nausea, vomiting, and diarrhoea (very common, especially during dose escalation) Reduced appetite and abdominal discomfort Constipation Risk of hypoglycaemia when used with insulin or sulphonylureas Pancreatitis and gallbladder disease have been reported Thyroid C-cell tumours have been observed in animal studies, though the relevance to humans is unknown Important safety considerations when using both treatments include: Mounjaro can reduce the effectiveness of oral contraceptives due to delayed gastric emptying
Each HCPCS Level II code is a single letter followed by four digits
This method injects the peptide directly into the abdominal cavity
You may even hear it called a healing peptide or the Wolverine peptide. However, those names can be misleading
Available from: 10 Ter Meulen BC, Maas ET, Vyas A, et al
86.Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC